Pharmacokinetics and bioavailability of carvedilol, a vasodilating beta-blocker
- 1 September 1987
- journal article
- clinical trial
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 33 (5) , 511-513
- https://doi.org/10.1007/bf00544245
Abstract
The pharmacokinetics and absolute bioavailability of carvedilol have been studied in 20 male healthy volunteers in a randomised 4-period, cross-over trial. Carvedilol 12,5 mg was given i.v., 50 mg was administered p.o. as a suspension and 25 and 50 mg were given in a capsule formulation. For the 50 mg capsule Cmax was 66 µg·l−1, tmax 1.2 h, t1/2 6.4 h. The t1/2 after i.v. administration was 2.4 h, CL 589 ml/min and Vz 132 l. The absolute bioavailability was 24% (50 mg capsule). The kinetics after the 25 and 50 mg capsules were consistent with dose linearity.Keywords
This publication has 5 references indexed in Scilit:
- High-performance liquid chromatograpic method for the determination of carvedilol and its desmethyl metabolite in body fluidsJournal of Chromatography B: Biomedical Sciences and Applications, 1987
- Clinical pharmacologic investigations with carvedilol, a new beta-blocker with direct vasodilator activityClinical Pharmacology & Therapeutics, 1986
- KINPAK--a new program package for standardized evaluation of kinetic parameters.1985
- Haemodynamic Effects of Carvedilol, A New Beta-Adrenoceptor Blocker and Precapillary Vasodilator in Essential HypertensionJournal Of Hypertension, 1984
- Clinical Pharmacokinetics of β-Adrenoreceptor Blocking DrugsClinical Pharmacokinetics, 1976